M-atrial natriuretic peptide

M-atrial natriuretic peptide is a synthetic analog of atrial natriuretic peptide engineered to be more resistant to enzymatic degradation and to provide enhanced therapeutic effects. MANP specifically activates the particulate guanylyl cyclase A (pGC-A) receptor, triggering increased production of cyclic guanosine monophosphate (cGMP). This mediates vasodilation, natriuresis, diuresis, and suppression of the renin-angiotensin-aldosterone system (RAAS). MANP has demonstrated blood pressure–lowering, lipolytic, and insulin-sensitizing effects in both animal models and clinical trials. Human studies indicate a single subcutaneous dose is safe, increases plasma cGMP, and improves blood pressure and metabolic parameters in patients with hypertension and metabolic syndrome. MANP may also enhance the effectiveness of diuretics like furosemide while suppressing compensatory aldosterone production[1][5][7].

Other names

MANP